Compositionalandstructuralanalysisofglycosaminoglycans in cell-derived extracellular matrices

João C. Silva^{1,2,4}, Marta S. Carvalho^{1,3,4}, Xiaorui Han², Ke Xia², Paiyz E. Mikael², Joaquim M. S. Cabral^{1,4}, Frederico Castelo Ferreira^{1,4} and Robert J. Linhardt^{2,3*}



Supplementary information

Supplementary Figure 1 Characterization of MSC isolated from bone marrow aspirates (BMSC) collected from a male donor (36 years) and of MSC isolated from synovium aspirates obtained from a male donor (28 years). (a) Immunophenotypic characterization of BMSC and SMSC assessed by flow cytometry. (b) Multi-lineage differentiation potential of BMSC and SMSC. Osteogenic, adipogenic and chondrogenic differentiation was confirmed after 14 days induction by ALP/von Kossa, Oil Red-O and Alcian Blue staining, respectively.



Supplementary Figure 2 Structures of AMAC derivatized disaccharides used in LC-MS/MS analysis.

Supplementary Table 1. Total GAG amounts obtained for the different cell-derived ECM produced from chondrocytes, BMSC and SMSC presented as ng of GAG/mg of dry ECM. Results are presented as mean \pm SD of three independent samples (n=3).

	Total GAG (ng/mg)								
	HS CS HA Total								
Chondrocyte-ECM	15.7 ± 3.5	86.4 ± 35.5	10.3 ± 5.6	112.4 ± 43.6					
BMSC-ECM	39.4 ± 16.4	79.4 ± 22.6	88.0 ± 19.6	206.8 ± 44.0					
SMSC-ECM	7.7 ± 0.8	34.6 ± 2.3	31.5 ± 8.4	73.8 ± 9.5					

Supplementary Table 2. HS and CS disaccharides amounts obtained for the different cell-derived ECM produced from chondrocytes, BMSC and SMSC presented as ng of GAG/mg of dry ECM. Results are presented as mean \pm SD of three independent samples (n=3).

HS disaccharide (ng/mg)									
	TriS	NS6S	NS2S	NS	2S6S	6 S	2 S	0S	
Chondrocyte- ECM	0.0 ± 0.0	0.3 ± 0.3	3.1 ± 0.3	3.2 ± 0.6	0.0 ± 0.0	0.4 ± 0.1	0.2 ± 0.2	8.4 ± 2.5	
BMSC-ECM	0.0 ± 0.0	0.2 ± 0.0	1.5 ± 0.9	11.1 ± 5.1	0.0 ± 0.0	1.1 ± 0.5	0.2 ± 0.2	25.3 ± 9.9	
SMSC-ECM	0.0 ± 0.0	0.1 ± 0.0	1.0 ± 0.1	1.1 ± 0.4	0.0 ± 0.0	0.3 ± 0.2	0.0 ± 0.0	5.2 ± 0.3	
	CS disaccharide (ng/mg)								
	TriS	2S4S	2S6S	4S6S	4 S	6 S	2 S	08	
Chondrocyte- ECM	0.0 ± 0.0	0.1 ± 0.0	2.2 ± 1.1	0.3 ± 0.2	22.8 ± 8.0	54.8±23.1	0.2 ± 0.2	6.0 ± 3.0	
BMSC-ECM	0.0 ± 0.0	0.2 ± 0.2	0.7 ± 0.6	0.3 ± 0.1	43.3±10.7	32.9±10.7	0.2 ± 0.2	1.9 ± 0.6	
SMSC-ECM	0.0 ± 0.0	0.0 ± 0.0	0.3 ± 0.1	0.9 ± 0.1	19.2 ± 1.5	13.3 ± 1.1	0.0 ± 0.0	0.9 ± 0.2	

Supplementary Table 3. Total GAG amounts presented as ng/dish for the different cell-derived ECM and respective cell culture monolayers prior to decellularization treatment. Results are presented as mean \pm SD of three independent samples (n=3).

	Total GAG (ng/dish)						
	HS	HS CS HA To					
Chondrocyte	209.5 ± 24.6	338.2 ± 42.2	125.0 ± 11.8	672.7 ± 70.9			
Chondrocyte-ECM	27.9 ± 6.3	153.6 ± 63.1	18.3 ± 10.0	199.8 ± 77.5			
BMSC	105.7 ± 11.5	113.9 ± 14.3	873.8 ± 160.3	1093.4 ± 184.4			
BMSC-ECM	42.4 ± 17.7	85.6 ± 24.3	94.9 ± 21.2	222.9 ± 47.5			
SMSC	57.8 ± 3.5	334.8 ± 178.7	86.5 ± 17.1	479.1 ± 199.3			
SMSC-ECM	14.0 ± 1.4	63.0 ± 4.2	57.5 ± 15.4	134.4 ± 17.3			

Supplementary Table 4. HS and CS disaccharide amounts presented as ng/dish for the different cell-derived ECM and respective cell culture monolayers prior to decellularization treatment. Results are presented as mean \pm SD of three independent samples (n=3).

HS disaccharide (ng/dish)									
	TriS	NS6S	NS2S	NS	2868	6 S	2S	08	
Chondrocyte	0.0±0.0	1.5±0.0	23.8±2.3	38.8±5.4	0.1±0.1	4.6±1.0	0.3±0.0	140.4±16.9	
Chondrocyte-ECM	0.0±0.0	0.5±0.5	5.4±0.5	5.7±1.1	0.0±0.0	0.8±0.3	0.4±0.3	14.9±4.5	
BMSC	0.0±0.0	0.4±0.0	16.6±2.1	28.8±3.2	0.1±0.1	0.0±0.0	0.0±0.0	59.8±6.1	
BMSC-ECM	0.0±0.0	0.2±0.0	1.6±1.0	11.9±5.5	0.0±0.0	1.2±0.5	0.2±0.2	27.2±10.7	
SMSC	0.1±0.0	0.2±0.2	4.3±0.4	7.5±1.3	0.0±0.0	0.8±0.5	3.4±0.6	41.5±0.9	
SMSC-ECM	0.0±0.0	0.1±0.1	1.7±0.2	2.1±0.8	0.0±0.0	0.5±0.4	0.1±0.0	9.4±0.5	
		CS	S disacch	aride (ng	g/dish)				
	TriS	2S4S	2S6S	4S6S	4 S	6S	2 S	08	
Chondrocyte	0.0±0.0	4.8±0.3	9.0±1.0	4.5±0.2	257.0±40.0	58.0±1.8	0.3±0.0	4.5±0.5	
Chondrocyte-ECM	0.0±0.0	0.2±0.1	3.9±2.0	0.6±0.4	40.5±14.1	97.4±41.1	0.4±0.3	10.6±5.4	
BMSC	0.0±0.0	1.1±0.3	1.0±0.1	1.3±0.4	85.5±11.7	20.9±3.4	0.0±0.0	4.1±0.5	
BMSC-ECM	0.0±0.0	0.2±0.2	0.7±0.6	0.3±0.1	46.7±11.5	35.5±11.5	0.2±0.2	2.0±0.7	
SMSC	0.1±0.0	0.2±0.0	2.0±0.3	4.6±0.7	233.3±114.4	74.9±55.8	3.4±0.6	16.3±7.0	
SMSC-ECM	0.0±0.0	0.1±0.0	0.5±0.2	1.6±0.1	35.0±2.7	24.1±2.0	0.1±0.0	1.6±0.4	

Supplementary Table 5. Average percentage GAG composition for the different cell-derived ECM and respective cell culture monolayers prior to decellularization treatment. Results are presented as mean \pm SD of three independent samples (n=3).

	Total GAG relative %								
	HS	HS CS HA							
Chondrocyte	31 ± 2	50 ± 1	19 ± 2						
Chondrocyte-ECM	15 ± 3	77 ± 2	9 ± 4						
BMSC	10 ± 1	10 ± 1	80 ± 2						
BMSC-ECM	18 ± 5	38 ± 6	43 ± 9						
SMSC	13 ± 5	68 ± 9	19 ± 4						
SMSC-ECM	10 ± 1	47 ± 6	42 ± 7						

Supplementary Table 6. Average percentage HS and CS disaccharide composition for the different cell-derived ECM and respective cell culture monolayers prior to decellularization treatment. Results are presented as mean \pm SD of three independent samples (n=3).

HS disaccharide relative %								
	TriS	NS6S	NS2S	NS	2S6S	6 S	2 S	0 S
Chondrocyte	0 ± 0	1 ± 0	11 ± 0	18 ± 1	0 ± 0	2 ± 0	0 ± 0	67 ± 1
Chondrocyte-ECM	0 ± 0	2 ± 2	20 ± 3	21 ± 1	0 ± 0	3 ± 1	1 ± 1	53 ± 4
BMSC	0 ± 0	0 ± 0	16 ± 0	27 ± 0	0 ± 0	0 ± 0	0 ± 0	57 ± 0
BMSC-ECM	0 ± 0	1 ± 0	4 ± 1	28 ± 2	0 ± 0	3 ± 0	0 ± 0	65 ± 3
SMSC	0 ± 0	0 ± 0	7 ± 0	13 ± 1	0 ± 0	1 ± 1	6 ± 1	72 ± 3
SMSC-ECM	0 ± 0	0 ± 0	12 ± 1	15 ± 4	0 ± 0	4 ± 3	0 ± 0	68 ± 3
		CS d	isacchar	ide relati	ve %			
	TriS	2S4S	2S6S	4S6S	4 S	6 S	2 S	0 S
Chondrocyte	0 ± 0	1 ± 0	3 ± 0	1 ± 0	76 ± 2	17 ± 2	0 ± 0	1 ± 0
Chondrocyte-ECM	0 ± 0	0 ± 0	2 ± 0	0 ± 0	27 ± 2	63 ± 1	0 ± 0	7 ± 1
BMSC	0 ± 0	1 ± 0	1 ± 0	1 ± 0	75 ± 1	18 ± 1	0 ± 0	4 ± 1
BMSC-ECM	0 ± 0	0 ± 0	1 ± 0	0 ± 0	55 ± 3	41 ± 2	0 ± 0	2 ± 0
SMSC	0 ± 0	0 ± 0	1 ± 0	2 ± 1	71 ± 4	21 ± 6	1 ± 0	5 ± 1
SMSC-ECM	0 ± 0	0 ± 0	1 ± 0	3 ± 0	56 ± 1	38 ± 1	0 ± 0	3 ± 1